Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study

Circulation

Volumn 108, Issue 6, 2003, Pages 684-690

  Okin, Peter M ^a   Devereux, Richard B ^a   Jern, Sverker ^b,d   Kjeldsen, Sverre E ^c   Julius, Stevo ^d   Nieminen, Markku S ^e   Snapinn, Steven ^f   Harris, Katherine E ^f   Aurup, Peter ^f   Edelman, Jonathan M ^f   Dahlöf, Björn ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Angiotensin; Electrocardiography; Hypertension; Hypertrophy

Indexed keywords

ATENOLOL; LOSARTAN; PLACEBO;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAPHY; ETHNOLOGY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0043164975     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000083724.28630.C3     Document Type: Article

References (23)

1. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy. J Am Coll Cardiol. 1998;31:383-390.
2. Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-1793.
3. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615-1621.
4. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:45-54.
5. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
6. Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580-586.
7. Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Am J Hypertens. 1998;11:1394-1404.
8. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of Mild Hypertension Study final results. JAMA. 1993;270:713-724.
9. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program: prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension. 1985;7:105-112.
10. Schmieder RE, Schneider MP, Martus P, et al. Reduction of left ventricular hypertrophy (LVH) by antihypertensive therapy: results of a metaanalysis of all double-blind randomized studies. J Am Coll Cardiol. 2001;37:261A-262A.
11. Dahlöf B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens. 2001;14:174-182.
12. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
13. Dahlöf B, Devereux R, de Faire U, et al. The Losartan Intervendon For Endpoint Reduction (LIFE) in Hypertension Study: rationale, design, and methods. Am J Hypertens. 1997;10:705-713.
14. Dahlöf B, Devereux RB, Julius S, et al. The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study: baseline characteristics of 9194 patients with left ventricular hypertrophy. Hypertension. 1998;32:989-997.
15. Okin PM, Roman MJ, Devereux RB, et al. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;25:417-423.
16. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161-186.
17. Schillaci G, Verdecchia P, Borgioni C, et al. Improved electrocardiographic diagnosis of echocardiographic left ventricular hypertrophy. Am J Cardiol. 1995;74:714-719.
18. Norman JE, Levy D. Improved detection of echocardiographic left ventricular hypertrophy: a correlated data base approach. J Am Coll Cardiol. 1995;26:1022-1029.
19. MacMahon S, Collins G, Rautaharju P, et al. Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1989;63:202-210.
20. Everett AD, Tufro-McReddie A, Fisher A, et al. Angiotensin inhibitors regressed cardiac hypertrophy and transforming growth factor-β1 expression. Hypertension. 1994;23:587-592.
21. 1R-AS gene therapy. Hypertension. 2002;39:969-975.
22. Davis CE. The effect of regression to the mean in epidemiologic and clinical studies. Am J Epidemiol. 1976;104:493-498.
23. Okin PM, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events: the LIFE Study. Circulation. 2002;106(suppl II):II-477.